Clinical Trials
2 trialsNCT02500927 2024-11-20
A Study of ASP8273 in Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor-Naïve Patients With Non-Small Cell Lung Cancer Harboring EGFR Mutations
Astellas Pharma Inc
Phase 2 Terminated
NCT03042013 2017-07-11
A Study for Subjects Who Are Participating in an Astellas-sponsored ASP8273 Study
Astellas Pharma Inc
Phase 2 Withdrawn